To examine RIG‐I expression in NPC chemoradiotherapy‐sensitive or resistant tissues, we used immunohistochemistry to quantitate RIG‐I expression in NPC tissues from patients with stable disease (SD) who were chemoradiotherapy resistant and from patients with partial remission (PR) or complete remission (CR). This evidence concerns the gene RIGI and nasopharyngeal carcinoma.